Gyrolab^® SpinBlog

12/14/2021

Anti-interferon autoantibodies play a major role in the age-related severity of COVID-19

11/15/2021

Matching microsampling with miniaturized bioanalysis is revolutionizing pharma biotherapeutic development

05/22/2021

Accurate ligand affinity determination: in-solution Adnectin KD measurement

05/21/2021

Accurate ligand affinity determination: high-affinity ligands for use in cancer immunotherapy

04/05/2021

Boost COVID-19 vaccine R&D with rapid serology tests and minimal sample and reagent consumption (Part III)

03/29/2021

Immunoassays to measure SARS-CoV-2 antibodies in serum (Part II)

03/23/2021

Serology tests in COVID-19 research and vaccine development (Part I)

12/09/2020

Capsid titer quantification for AAV-based therapeutics

11/12/2020

A new spin on ultra-high biomolecular affinity determination

06/05/2020

Boosting vaccine development and production in a post-pandemic era with fast, high-performance immunoassays: Part I

06/05/2020

Boosting vaccine development and production in a post-pandemic era with fast, high-performance immunoassays: Part II

04/06/2020

How to think about HCP impurity testing

04/06/2020

Enhancing the productivity of immunoassays: a 2-plex Gyrolab assay for both preclinical and clinical studies

02/27/2020

How to be confident in immunoassay determination of free versus bound target or drug

02/19/2020

Improving quality and speed in immunoassay development, validation, and routine use

02/19/2020

Weighing up the advantages and disadvantages of multiplex assays

02/19/2020

Solutions to immunoassay interference, cross reactivity and other challenges

01/15/2020

Putting a new spin on immunoassays for cell and gene therapy – Part 2

01/15/2020

Putting a new spin on immunoassays for gene therapy – Part 1

06/11/2019

Next generation antibody therapeutics move into prokaryotes

07/24/2017

Ligand binding assays for regulated bioanalysis

05/15/2017

How to get it right the first time

01/26/2016

ADME of therapeutic proteins